Collectively, these results confirm that the ability of PTP 9 to sensitize cancer cells to the effects of IFNγ and TNFα are not restricted to melanoma cells but extend to other solid tumors, many of which exhibit resistance to ICI therapy. The gene discussed is IFNG; the disease is melanoma.